We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.85%
2 Miscellaneous 12.14%
3 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
101
Madrigal Pharmaceuticals
MDGL
$12.5B
$861K 0.01%
57,762
– –
CLLS
102
Cellectis
CLLS
$184M
$848K 0.01%
50,000
– –
TENX icon
103
Tenax Therapeutics
TENX
$69.6M
$819K 0.01%
13
– –
IMDZ
104
DELISTED
Immune Design Corp.
IMDZ
$819K 0.01%
148,937
– –
INFI
105
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$784K 0.01%
580,400
– –
ALDX icon
106
Aldeyra Therapeutics
ALDX
$88.1M
$760K 0.01%
142,000
– –
TARA icon
107
Protara Therapeutics
TARA
$231M
$740K 0.01%
9,735
+2,270
+30% +$718K
XLRN
108
DELISTED
Acceleron Pharma
XLRN
$734K 0.01%
28,765
– –
AFMD
109
DELISTED
Affimed
AFMD
$720K 0.01%
40,000
– –
CBAY
110
DELISTED
Cymabay Therapeutics
CBAY
$535K 0.01%
+309,268
New +$546K
CMRX
111
DELISTED
Chimerix, Inc.
CMRX
$530K 0.01%
115,216
– –
ABUS icon
112
Arbutus Biopharma
ABUS
$1.02B
$442K ﹤0.01%
180,582
– –
ALNY icon
113
Alnylam Pharmaceuticals
ALNY
$33.5B
$425K ﹤0.01%
11,340
– –
ADAP
114
DELISTED
Adaptimmune Therapeutics
ADAP
$405K ﹤0.01%
100,000
– –
FMI
115
DELISTED
Foundation Medicine, Inc.
FMI
$370K ﹤0.01%
20,892
– –
BDSI
116
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$368K ﹤0.01%
210,021
– –
CCXI
117
DELISTED
ChemoCentryx, Inc.
CCXI
$363K ﹤0.01%
49,064
– –
APTO
118
DELISTED
Aptose Biosciences, Inc.
APTO
$359K ﹤0.01%
574
-324
-36% -$202K
WINT
119
DELISTED
Windtree Therapeutics Inc
WINT
$319K ﹤0.01%
254,973
– –
SRRA
120
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$298K ﹤0.01%
5,000
– –
DVAX
121
DELISTED
Dynavax Technologies
DVAX
$296K ﹤0.01%
75,000
– –
LJPC
122
DELISTED
La Jolla Pharmaceutical Company
LJPC
$241K ﹤0.01%
13,746
– –
BGMSP
123
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$82K ﹤0.01%
13,253
– –
BTX.WS
124
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$14K ﹤0.01%
20,084
– –
ARWR icon
125
Arrowhead Research
ARWR
$11.4B
– –
-1,856,967
Closed -$13.6M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Baker Bros. Advisors held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Baker Bros. Advisors opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Baker Bros. Advisors's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Baker Bros. Advisors's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Baker Bros. Advisors fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 7 in Q4 2016.
  • Baker Bros. Advisors's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.